US3183159A - Stabilized partial thromboplastin reagent - Google Patents

Stabilized partial thromboplastin reagent Download PDF

Info

Publication number
US3183159A
US3183159A US181202A US18120262A US3183159A US 3183159 A US3183159 A US 3183159A US 181202 A US181202 A US 181202A US 18120262 A US18120262 A US 18120262A US 3183159 A US3183159 A US 3183159A
Authority
US
United States
Prior art keywords
partial thromboplastin
reagent
test
stabilized
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US181202A
Inventor
Heron O Singher
Jr Ralph Wellerson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Priority to US181202A priority Critical patent/US3183159A/en
Application granted granted Critical
Publication of US3183159A publication Critical patent/US3183159A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Definitions

  • the present invention relates to a method of stabilizing partial thrombop'lasti'n reagent and to the stabilized partial thromboplastin reagent so obtained.
  • the partial thromboplastin time test was originally developed by Langdell, Wagner and Brinkhous as a method of following the therapy of hemophilic patients. These investigators found this test to be extremely sensitive to changes in Factor VIII brought about by whole blood or plasma transfusions. Extensive studies of the partial thromboplastin timetest by Rodman, Barrow and Graham have shown that this test is sensitive to plasma deficiencies of Factor II (Prothrombin), Factor V (AcG, Labile Factor), Factor VIII, Factor IX (PTC), Factor X (Stuart Prower Factor), Factor XI (PTA), and Factor XII (Hageman Factor). In patients deficient in any of the above factors prolonged partial thromboplastin time values are obtained.
  • partial thromboplastin test has not been generally employed as widely as might be warranted for the reason that the partial thromboplastin reagent must be freshly prepared and standardized just prior to use or else prepared in a dry form necessitating reconstitution.
  • a partial thromboplastin test reagent may be stabilized by the addition to the reagent of small quantities of sodium ethylmercurithiolsalicylate having the formula:
  • the sodium ethylmercurithiolsalicylate acts as an effective stabilizing agent without effecting the activity of the partial thromboplastin reagent or altering the partial thromboplastin time. Larger amounts of the sodium ethylmercurithiolsalicylate are no more effective in stabilizing the partial thromboplastin reagent and it is recommended that greater concentrations of this sodium salt (more than 0.01%) be avoided as the mercury ion in higher concentrations could interfere with the partial thromboplastin test.
  • the stable partial thrombopla-s tin reagent of the present invention is an ether extract of acetone dried brain tissue.
  • Bovine brain is used as the starting material. The meninges are removed, and the brain is washed under tap water; About 100 grams of wet brain are covered with acetone and allowed to stand for 1 hour. The tissue is gefitly mashed under acetone in a mortar with a pestle. The supernatant is decanted and discarded and the process repeated until the tissue becomes flaky and the acetone remains clear. The tissue is then ground into small particles and spread on a flat pan to dry. The yield of dry powder so obtained is 18 grams.
  • EXAMPLE II The partial thromboplastin test Human blood samples are collected using as an anticoagulant a 0.1 M aqueous solution of sodium oxalate. The anticoagulant is added to the blood in the proportion of one part by volume anticoagulant to nine parts by volume of blood. The blood is then centrifuged and the plasma is separated.
  • the human blood plasma 0.1 ml., collected as de scribed above, is placed in a 10 x mm. test tube.
  • 0.1 ml. of the partial thromboplastin test reagent prepared as described in Example I above is added to the test tube (0.1 ml. of 0.02 CaCl and a stop watch is started.
  • the tube is tapped gently 2 or 3 times to mix the materials and placed in the water bath until the stop watch reads 60 seconds.
  • the test tube is then removed from the water bath and gently tilted until a clot forms.
  • the stop watch is stopped at this point and the elapsed time is recorded as the partial thromboplastin time.
  • the test is performed both on a control and patients plasma. The normal range is 60 to seconds.
  • EXAMPLE III Two lots of partial thromboplas'tin reagent prepared as described in Example I above, but at different times, are tested immediately after their preparation with normal human plasma.
  • the partial thromboplastin time in each instance averages 72-75 seconds.
  • the quantities of partial thromboplastin reagent from each batch are sealed in clear glass vials and stored for 14 months at 5 C.
  • the following table shows the partial thromboplastin time (PPT) in seconds as determined with normal human plasma after 14 months storage. It
  • a reagent for the partial thromboplastin time test comprising ether soluble cephalin derived from brain tissue stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.
  • a reagent for the partial thromboplastin time test comprising an ether extract of brain tissue that has been previously extracted with acetone, stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.
  • a reagent according to claim 2 wherein the brain tissue is bovine brain tissue.
  • a reagent for the partial thromboplastin time test comprising a suspension of ether soluble cephalin derived from brain tissue in physiological saline, stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.
  • a reagent for the partial thromboplastin time test comprising a physiological saline suspension of an ether extract of brain tissue that has previously been extracted with acetone, stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Description

United States Patent M 3,183,159 STABILIZED PARTIAL THROMBOPLASTIN REAGENT Heron 0. Singher, Plainfield, and Ralph Wellerson, Jr.,
Bound Brook, N.J., assignors to Ortho Pharmaceutical Corporation, a corporation of New Jersey No Drawing. Filed Mar. 20, 1962, Ser. No. 181,202
6 Claims. (Cl. 167-74) The present invention relates to a method of stabilizing partial thrombop'lasti'n reagent and to the stabilized partial thromboplastin reagent so obtained.
The partial thromboplastin time testwas originally developed by Langdell, Wagner and Brinkhous as a method of following the therapy of hemophilic patients. These investigators found this test to be extremely sensitive to changes in Factor VIII brought about by whole blood or plasma transfusions. Extensive studies of the partial thromboplastin timetest by Rodman, Barrow and Graham have shown that this test is sensitive to plasma deficiencies of Factor II (Prothrombin), Factor V (AcG, Labile Factor), Factor VIII, Factor IX (PTC), Factor X (Stuart Prower Factor), Factor XI (PTA), and Factor XII (Hageman Factor). In patients deficient in any of the above factors prolonged partial thromboplastin time values are obtained. However, the partial thromboplastin test has not been generally employed as widely as might be warranted for the reason that the partial thromboplastin reagent must be freshly prepared and standardized just prior to use or else prepared in a dry form necessitating reconstitution.
It is an object of the present invention, therefore, to provide a partial thromboplastin reagent that will remain stable in the liquid form upon storage over an extended period of time so that accurate results will be obtained irrespective of the time that the reagent is used.
It has now been discovered that a partial thromboplastin test reagent may be stabilized by the addition to the reagent of small quantities of sodium ethylmercurithiolsalicylate having the formula:
When present at a concentration of 1 part in 10,000 (0.01%), the sodium ethylmercurithiolsalicylate acts as an effective stabilizing agent without effecting the activity of the partial thromboplastin reagent or altering the partial thromboplastin time. Larger amounts of the sodium ethylmercurithiolsalicylate are no more effective in stabilizing the partial thromboplastin reagent and it is recommended that greater concentrations of this sodium salt (more than 0.01%) be avoided as the mercury ion in higher concentrations could interfere with the partial thromboplastin test. The addition of appreciably smaller quantities of sodium ethylmercurithiolsalicylate (less than 0.001%) should also be avoided as too little a quantity of sodium ethylmercurithiolsalicylate may not provide the desired stability under all conditions of storage.
In order that those skilled in the art may better understand how the present invention may be carried out, the following examples are given by way of illustration an not by way of limitation.
3,183,159 Patented May 11, 1965 EXAMPLE 1' Preparation of partial thromboplastin reagent The stable partial thrombopla-s tin reagent of the present invention is an ether extract of acetone dried brain tissue. Bovine brain is used as the starting material. The meninges are removed, and the brain is washed under tap water; About 100 grams of wet brain are covered with acetone and allowed to stand for 1 hour. The tissue is gefitly mashed under acetone in a mortar with a pestle. The supernatant is decanted and discarded and the process repeated until the tissue becomes flaky and the acetone remains clear. The tissue is then ground into small particles and spread on a flat pan to dry. The yield of dry powder so obtained is 18 grams. The 18 grams of dry brain powder (in an Erlenmeyer flask) is covered with ether, and stoppered. The dry-material is suspended by shaking and allowed to stand overnight at room temperature. The following morning, the supernatant is filtered until clear, and the clear filtrate evaporated to dryness with a stream of air. The dry residue is washed twice with 40 ml. boiling acetone, then air-dried. This residue (cephalin) is a pale yellow waxy material and weighs 3.0 grams. This material is suspended in 3 ml. of physiological saline, and the volume brought to 100 ml. by the slow addition of physiological saline with careful mixing. The 3 percent suspension so obtained is opaque and white in color.
One gram of sodium ethylmercurithiolsalicylate is dissolved in 10,000 grams of physiological saline, and 1,900 ml. of the solution so obtained is added with stirring to the 3% suspension of cephalin (100 ml.) described above. The diluted suspension is sealed in vials and may be stored indefinitely at 5 C. without loss of activity. This product may be used as a reagent in running the partial thromboplastin test.
EXAMPLE II The partial thromboplastin test Human blood samples are collected using as an anticoagulant a 0.1 M aqueous solution of sodium oxalate. The anticoagulant is added to the blood in the proportion of one part by volume anticoagulant to nine parts by volume of blood. The blood is then centrifuged and the plasma is separated.
The human blood plasma, 0.1 ml., collected as de scribed above, is placed in a 10 x mm. test tube. To this is added 0.1 ml. of the partial thromboplastin test reagent prepared as described in Example I above, and the test tube is placed in a water bath heated to 37 C. for 30 seconds. Calcium chloride solution is then added to the test tube (0.1 ml. of 0.02 CaCl and a stop watch is started. The tube is tapped gently 2 or 3 times to mix the materials and placed in the water bath until the stop watch reads 60 seconds. The test tube is then removed from the water bath and gently tilted until a clot forms. The stop watch is stopped at this point and the elapsed time is recorded as the partial thromboplastin time. The test is performed both on a control and patients plasma. The normal range is 60 to seconds.
EXAMPLE III Two lots of partial thromboplas'tin reagent prepared as described in Example I above, but at different times, are tested immediately after their preparation with normal human plasma. The partial thromboplastin time in each instance averages 72-75 seconds.
The quantities of partial thromboplastin reagent from each batch are sealed in clear glass vials and stored for 14 months at 5 C. The following table shows the partial thromboplastin time (PPT) in seconds as determined with normal human plasma after 14 months storage. It
3 will be noted that the partial thromboplastin reagent has not lost activity during storage.
Vial PTT, Lot 1 PTT, Lot 2 71. 7 7o. 4 72. 7 70. 5 70. 5 71.0 71. 9 74.0 73. 7 74. 3 72. 0 75. 4 70. 6 70. 9 73. 3 75. 4 70. 0 69.9 71. 2 69. 4 70.8 73.8 75. 4 s1. 2 67.9 70. 1 73. 4 74. 2 s1. 0 74. 1 74. 0 72. 9 72. 0 74. 8 7G. 1 s0. 0 77. 7 79. 2 74. 0 80.3
The invention described and illustrated hereinbefore and secured by these Letters Patent is defined in the following patent claims.
What is claimed is:
1. A reagent for the partial thromboplastin time test comprising ether soluble cephalin derived from brain tissue stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.
2. A reagent for the partial thromboplastin time test comprising an ether extract of brain tissue that has been previously extracted with acetone, stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.
3. A reagent according to claim 2 wherein the brain tissue is bovine brain tissue.
4. A reagent for the partial thromboplastin time test comprising a suspension of ether soluble cephalin derived from brain tissue in physiological saline, stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.
5. A reagent for the partial thromboplastin time test comprising a physiological saline suspension of an ether extract of brain tissue that has previously been extracted with acetone, stabilized by the presence of from about 0.001% to about 0.01% sodium ethylmercurithiolsalicylate.
6. A reagent according to claim 5 wherein the brain tissue is bovine brain tissue.
References Cited in the file of this patent UNITED STATES PATENTS 2,516,216 Kazal July 25, 1960

Claims (1)

1. A REAGENT FOR THE PARTIAL THROMBOPLASTIN TIME TEST COMPRISING ETHER SOLUBLE CEPHALIN DERIVED FROM BRAIN TISSUE STABILIZED BY THE PRESENCE OF FROM ABOUT 0.001% TO ABOUT 0.01% SODIUM ETHYLMERCURITHIOSALICYLATE.
US181202A 1962-03-20 1962-03-20 Stabilized partial thromboplastin reagent Expired - Lifetime US3183159A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US181202A US3183159A (en) 1962-03-20 1962-03-20 Stabilized partial thromboplastin reagent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US181202A US3183159A (en) 1962-03-20 1962-03-20 Stabilized partial thromboplastin reagent

Publications (1)

Publication Number Publication Date
US3183159A true US3183159A (en) 1965-05-11

Family

ID=22663307

Family Applications (1)

Application Number Title Priority Date Filing Date
US181202A Expired - Lifetime US3183159A (en) 1962-03-20 1962-03-20 Stabilized partial thromboplastin reagent

Country Status (1)

Country Link
US (1) US3183159A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980432A (en) * 1973-04-02 1976-09-14 Behringwerke Aktiengesellschaft Partial thromboplastin, its use as diagnostic agent and process for preparing it
EP0107383A1 (en) * 1982-09-29 1984-05-02 Ortho Diagnostic Systems Inc. Diagnostic activated partial thromboplastin reagent
US4458015A (en) * 1981-04-02 1984-07-03 Boehringer Mannheim Gmbh Reagent for the optical determination of the blood coagulation
EP2072624A1 (en) * 2007-12-21 2009-06-24 Siemens Healthcare Diagnostics Products GmbH Long-term stable thromboplastin reagent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2516216A (en) * 1947-06-24 1950-07-25 Sharp & Dohme Inc Thromboplastin as testing agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2516216A (en) * 1947-06-24 1950-07-25 Sharp & Dohme Inc Thromboplastin as testing agent

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980432A (en) * 1973-04-02 1976-09-14 Behringwerke Aktiengesellschaft Partial thromboplastin, its use as diagnostic agent and process for preparing it
US4458015A (en) * 1981-04-02 1984-07-03 Boehringer Mannheim Gmbh Reagent for the optical determination of the blood coagulation
EP0107383A1 (en) * 1982-09-29 1984-05-02 Ortho Diagnostic Systems Inc. Diagnostic activated partial thromboplastin reagent
EP2072624A1 (en) * 2007-12-21 2009-06-24 Siemens Healthcare Diagnostics Products GmbH Long-term stable thromboplastin reagent
US20090162880A1 (en) * 2007-12-21 2009-06-25 Andreas Rechner Thromboplastin reagent with long-term stability
US8617834B2 (en) 2007-12-21 2013-12-31 Siemens Healthcare Diagnostics Products Gmbh Thromboplastin reagent with long-term stability

Similar Documents

Publication Publication Date Title
US3458397A (en) Process for producing osteogenic material
Kekwick Observations on the crystallizable albumin fraction of horse serum
JPS5495715A (en) Antithrombin agent and its preparation
TAYLOR et al. Adrenotrophic activity of human blood
JPH0339267B2 (en)
US3933996A (en) Composition comprising radioactive labeled-fibrinogen and albumin
JPS6236502B2 (en)
US3183159A (en) Stabilized partial thromboplastin reagent
Grove et al. The loss of sodium and potassium during the dry ashing of animal tissue
IL49391A (en) 6-chloro-2-(1-piperazinyl)pyrazine and acid addition salts, their preparation and pharmaceutical compositions containing them
Fricke Kinetics of thermal denaturation of X-rayed egg albumin
US2530372A (en) Aluminum penicillin
US2922745A (en) Purification of profibrinolysin
Galaske Renal functional maturation: renal handling of proteins by mature and immature newborns
US2312195A (en) Salts of dextro-ascorbic acid and method of preparing same
Atkins Jr et al. Isotopic exchange reactions of zinc chelate complexes
US2516216A (en) Thromboplastin as testing agent
US2369111A (en) Blood clotting accelerator
Bowie et al. Transfusion and autotransfusion of plasma in von Willebrand's disease
Monash Use of insoluble penicillin salts for the prolongation of penicillin blood levels
SU442802A1 (en) Protein drug-hemulen
Bessler et al. Quantitative determination of human plasma erythropoietin using embryonic mouse liver erythroblasts
US2921000A (en) Thromboplastin
ES2129023T3 (en) DERIVATIVES OF BENZO (C) FENANTRIDINIO.
US2395069A (en) Preparations of arsenic and antimony